Our product pipeline includes several products already
commercialized in diferent indications. We are preparing for a pre-IND meeting with the FDA for our leading compound.
A product dedicated to prevent
and treat a condition caused by the use of fertility drugs. The company plans to submit the IND later in 2017.
product candidates are being evaluated for development STI2833 and STI2610. The first product to be used in Controlled
Ovarian Stimulation (COS) in ART and the second one an innovative delivery system for administering a hormone in patients
undergoing OI and ART.
Inc. - All rights reserved
10 Keith Way, Suite 3. - Hingham, MA 02043 - USA - Ph.: +1-781-556-5012 - Fax: +1-781-735-5899